



Getting to Know DEXYCU

A Prescribing Information guide
for healthcare professionals



DEXYCU[™]
(dexamethasone intraocular
suspension) 9%

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DEXYCU™ safely and effectively. See full prescribing information for DEXYCU.

DEXYCU (dexamethasone intraocular suspension) 9%, for intraocular administration
Initial U.S. Approval: 1958

INDICATIONS AND USAGE

DEXYCU is a corticosteroid indicated for the treatment of postoperative inflammation (1).

DOSAGE AND ADMINISTRATION

- For intraocular administration (2).
- Administer 0.005 mL of DEXYCU into the posterior chamber inferiorly behind the iris at the end of ocular surgery (2).

DOSAGE FORMS AND STRENGTHS

Intraocular suspension: 9% equivalent to dexamethasone 103.4 mg/mL in a single-dose vial provided in a kit (3).

CONTRAINDICATIONS----- None (4).

WARNINGS AND PRECAUTIONS-----

- Increase in intraocular pressure (IOP): Monitor for increases in IOP (5.1).
- Delayed Healing: Monitor for delayed healing (5.2).
- Infection Exacerbation: Monitor and treat for any exacerbations of bacterial, viral or fungal infections (5.3).
- Cataract Progression: Cataracts may develop or progress in phakic patients (5.4).

ADVERSE REACTIONS-----

In controlled studies, the most common adverse reactions reported by 5-15% of patients were intraocular pressure increased, corneal edema and iritis (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact EyePoint Pharmaceuticals US at 1-833-EYEPOINT (1-833-393-7646) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Revised: 12/2018

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Dosing Information

2.2 Preparation and Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Increase in Intraocular Pressure

5.2 Delayed Healing

5.3 Exacerbation of Infection

5.4 Cataract Progression

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

*Sections or subsections omitted from the full prescribing information are not listed.

HIGHLIGHTS OF PRESCRIBING INFORMATION

FULL PRESCRIBING INFORMATION: TABLE OF CONTENTS

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

DEXYCU (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation.

2 DOSAGE AND ADMINISTRATION


2.1 Dosing Information

DEXYCU should be administered as a single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).

2.2 Preparation and Administration

Each kit of DEXYCU is for a single administration. After preparation, 0.005 mL will be administered.

The DEXYCU administration kit contains the following items:



1. One glass vial: 0.5 mL of DEXYCU
2. One sterile 1-mL syringe
3. One sterile syringe guide
4. One sterile syringe ring
5. One sterile 18-gauge needle (1½ inches long), plastic cap attached
6. One sterile 25-gauge bent cannula (8 mm long), plastic cap attached

INDICATION AND USAGE

DEXYCU is indicated for the treatment of postoperative inflammation.

DOSAGE AND ADMINISTRATION

DEXYCU should be administered as a single dose in the posterior chamber at the end of surgery at a dose of 0.005 mL of dexamethasone 9% (equivalent to 517 mcg).

PREPARATION AND ADMINISTRATION


This section highlights the 6 items required and the 11 steps needed to prepare and administer DEXYCU.

Step 1.

Prepare a sterile field.

Remove the components of the administration kit from their respective pouches:

- syringe
- syringe guide
- syringe ring
- needle
- cannula




Place onto the sterile field.

Step 2.

Withdraw the syringe plunger approximately 1 inch.

Place the syringe ring on the plunger (slit facing the plunger).

Apply slight downward pressure until the syringe ring “snaps” into place.




Step 3.

Place the 18-gauge needle firmly on the syringe.

Remove the cap from the needle.

Depress the plunger completely and then withdraw the plunger to fill the syringe with air.




STEP 1: PREPARING A STERILE FIELD

STEPS 2 & 3: PREPARING THE SYRINGE

Step 4.

Vigorously shake the vial of DEXYCU sideways for a minimum of 30 seconds.

The suspended drug material must be used immediately after shaking.



Step 5.

Remove the blue plastic flip-cap from the vial and wipe the top of rubber stopper with an alcohol pad.

Invert the vial.




Step 6.

Insert the needle into the vial and inject the air into the vial.

Making sure the needle tip is immersed in the drug material pooled in the neck of the inverted vial, fill the syringe by slowly withdrawing the plunger approximately 0.2 mL.

Remove the needle from the vial and discard the unused portion in the vial.



STEPS 4 & 5: PREPARING THE VIAL

STEP 6: DRAWING DEXYCU


Step 7.

Remove the needle from the syringe.

Firmly place the cannula on the syringe and remove the plastic cap.


Hold the syringe vertically with the cannula pointing up.

Depress the plunger to expel air bubbles from syringe.



Step 8.

Affix the syringe guide over the syringe ring on the plunger.




Step 9.

Depress the plunger until the syringe guide/ring mechanism comes gently into contact with the flange of the syringe.

Lightly tap/flick the barrel of the syringe to remove any excess drug from the tip of the cannula.

Do not wipe or touch the tip of the cannula to remove excess drug.




STEPS 7, 8, & 9: PREPARING THE SYRINGE FOR INJECTION

Step 10.

Remove the syringe guide, leaving the syringe ring in place.

Caution to not move the plunger. The space between the syringe ring and the top of the plunger is the medication injection volume that will be applied to the patient's eye.

The syringe is now ready for injection.




STEP 10: CONTINUATION OF INJECTION PREPARATION

Step 11.

In a single slow motion, inject 0.005 mL of the drug material behind the iris in the inferior portion of the posterior chamber. If the sphere of administered drug after intraocular injection appears to be larger than 2 mm in diameter, excess drug material may be removed by irrigation and aspiration in the sterile surgical setting

PLEASE NOTE: Some drug material will remain in the syringe after the injection—this is necessary for accurate dosing. Discard unused portion remaining in the syringe after administration.



STEP 11: ADMINISTRATION OF DEXYCU

PLEASE NOTE: Some drug material will remain in the syringe after the injection—this is necessary for accurate dosing. Discard unused portion remaining in the syringe after administration.

3 DOSAGE FORMS AND STRENGTHS

DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Increase in Intraocular Pressure

Prolonged use of corticosteroids including DEXYCU may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma.

5.2 Delayed Healing

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of corticosteroids.

5.3 Exacerbation of Infection

The use of DEXYCU, as with other ophthalmic corticosteroids, is not recommended in the presence of most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures.

Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection.

5.4 Cataract Progression

The use of corticosteroids in phakic individuals may promote the development of posterior subcapsular cataracts.

DOSAGE FORMS AND STRENGTHS

DEXYCU contains dexamethasone 9% for administration as a single 517 mcg dose.

CONTRAINDICATIONS

There are no contraindications for DEXYCU.

WARNINGS AND PRECAUTIONS

- Increased intraocular pressure
- Delayed healing
- Exacerbation of infection
- Cataract progression

6 ADVERSE REACTIONS

The following adverse reactions are described elsewhere in the labeling:

- Increase in Intraocular Pressure [see *Warning and Precautions (5.1)*]
- Delayed Healing [see *Warnings and Precautions (5.2)*]
- Infection Exacerbation [see *Warnings and Precautions (5.3)*]
- Cataract Progression [see *Warnings and Precautions (5.4)*]

6.1 Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The following adverse events rates are derived from three clinical trials in which 339 patients received the 517 microgram dose of DEXYCU. The most commonly reported adverse reactions occurred in 5-15% of subjects and included increases in intraocular pressure, corneal edema and iritis. Other ocular adverse reactions occurring in 1-5% of subjects included, corneal endothelial cell loss, blepharitis, eye pain, cystoid macular edema, dry eye, ocular inflammation, posterior capsule opacification, blurred vision, reduced visual acuity, vitreous floaters, foreign body sensation, photophobia, and vitreous detachment.

ADVERSE REACTIONS

The adverse reactions presented here are specific to 339 patients who received the DEXYCU 517-mcg dose in 3 clinical trials.

The most commonly reported adverse reactions in 5% to 15% of patients were increases in intraocular pressure, corneal edema, and iritis.

Additional adverse reactions reported in 1% to 5% of patients were corneal endothelial cell loss, blepharitis, eye pain, cystoid macular edema, dry eye, ocular inflammation, posterior capsule opacification, blurred vision, reduced visual acuity, vitreous floaters, foreign body sensation, photophobia, and vitreous detachment.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no adequate and well-controlled studies of DEXYCU (dexamethasone intraocular suspension) 9% in pregnant women. Topical ocular administration of dexamethasone in mice and rabbits during the period of organogenesis produced cleft palate and embryofetal death in mice and malformations of abdominal wall/intestines and kidneys in rabbits at doses 7 and 5 times higher than the injected recommended human ophthalmic dose (RHOD) of DEXYCU (517 micrograms dexamethasone), respectively [see Data].

In the US general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

Topical ocular administration of 0.15% dexamethasone (0.75 mg/kg/day) on gestational days 10 to 13 produced embryofetal lethality and a high incidence of cleft palate in mice. A dose of 0.75 mg/kg/day in the mouse is approximately 7-times the injected RHOD of DEXYCU, on a mg/m² basis. In rabbits, topical ocular administration of 0.1% dexamethasone throughout organogenesis (0.20 mg/kg/day on gestational day 6, followed by 0.13 mg/kg/day on gestational days 7 – 18) produced intestinal anomalies, intestinal aplasia, gastroschisis and hypoplastic kidneys. A dose of 0.13 mg/kg/day in the rabbit is approximately 5-times the injected RHOD of DEXYCU, on a mg/m² basis. A no-observed-adverse-effect-level (NOAEL) was not identified in the mouse or rabbit studies.

8.2 Lactation

Risk Summary

Systemically administered corticosteroids are present in human milk and can suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. There is no information regarding the presence of injected DEXYCU in human milk, the effects on breastfed infants, or the effects on milk production to inform risk of DEXYCU to an infant during lactation. The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for DEXYCU and any potential adverse effects on the breastfed child from DEXYCU.

8.4 Pediatric Use

Safety and effectiveness of DEXYCU in pediatric patients have not been established.

8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between older and younger patients.

USE IN SPECIFIC POPULATIONS


Review this information when considering DEXYCU in the following populations:

- Pregnancy
 - There are no adequate and well-controlled studies of DEXYCU (dexamethasone intraocular suspension) 9% in pregnant women
- Lactation
 - There is no information regarding the presence of injected DEXYCU in human milk, the effects on breastfed infants, or the effects on milk production to inform risk of DEXYCU to an infant during lactation
- Pediatric use
 - Safety and effectiveness of DEXYCU in pediatric patients have not been established
- Geriatric use
 - No overall differences in safety or effectiveness have been observed between older and younger patients

11 DESCRIPTION

DEXYCU (dexamethasone intraocular suspension) 9% is a corticosteroid, sterile, white to off-white opaque suspension for intraocular administration. Each vial of DEXYCU contains 0.5 mL of 9% w/w dexamethasone suspension equivalent to 51.7 mg of dexamethasone. The inactive ingredient is acetyl triethyl citrate. DEXYCU does not contain an antimicrobial preservative.

The chemical name of dexamethasone is pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11 β ,16 α)-. It has a molecular formula of C₂₂H₂₉FO₅ and a molecular weight of 392.46 grams per mole. Its structural formula is:



12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Dexamethasone is a corticosteroid. Corticosteroids have been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

12.3 Pharmacokinetics

Systemic exposure to dexamethasone was evaluated in a subgroup of patients enrolled in two studies (n=25 for the first study and n=13 for the second study). The patients received a single intraocular injection of DEXYCU containing 342 mcg or 517 mcg of dexamethasone at the end of cataract surgery and blood samples were collected prior to surgery and at several time points post-surgery between Day 1 and up to Day 30. In the first study, the dexamethasone plasma concentrations on post-surgery Day 1 ranged from 0.09 to 0.86 ng/mL and from 0.07 to 1.16 ng/mL following administration of DEXYCU 342 mcg and 517 mcg, respectively. In the second study, dexamethasone plasma concentrations on post-surgery Day 1 ranged from 0.349 to 2.79 ng/mL following administration of DEXYCU 517 mcg. In both the studies, dexamethasone plasma concentrations declined over time and very few patients had quantifiable dexamethasone plasma concentrations at the final time point of sampling (Day 15 or Day 30).

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Animal studies have not been conducted to determine whether DEXYCU has the potential for carcinogenesis or mutagenesis. Fertility studies have not been conducted in animals

DESCRIPTION

DEXYCU is a white to off-white opaque suspension containing 0.5 mL of 9% dexamethasone. Each vial of DEXYCU contains 0.5 mL of 9% w/w dexamethasone suspension equivalent to 51.7 mg of dexamethasone.

CLINICAL PHARMACOLOGY

Mechanism of Action

Dexamethasone is a corticosteroid. Corticosteroids have been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

Pharmacokinetics

Systemic exposure to dexamethasone was evaluated in a subgroup of patients enrolled in two studies (n=25 for the first study and n=13 for the second study). The patients received a single intraocular injection of DEXYCU containing 517 mcg of dexamethasone at the end of cataract surgery and blood samples were collected prior to surgery and at several time points post-surgery between Day 1 and up to Day 30. In the first study, the dexamethasone plasma concentrations on post-surgery Day 1 ranged from 0.07 to 1.16 ng/mL following administration of DEXYCU 517 mcg. In the second study, dexamethasone plasma concentrations on post-surgery Day 1 ranged from 0.349 to 2.79 ng/mL following administration of DEXYCU 517 mcg. In both the studies, dexamethasone plasma concentrations declined over time and very few patients had quantifiable dexamethasone plasma concentrations at the final time point of sampling (Day 15 or Day 30).

NONCLINICAL TOXICOLOGY

14 CLINICAL STUDIES

Clinical efficacy was evaluated in a randomized, double-masked, placebo-controlled trial (NCT02006888) in which subjects received either DEXYCU or placebo (vehicle). A dose of 5 microliters of DEXYCU (equivalent to 517 micrograms of dexamethasone), a dose equivalent to 342 micrograms of dexamethasone or vehicle was administered by the physician at the end of the surgical procedure. The primary efficacy endpoint for the study was the proportion of patients with anterior chamber cell clearing (i.e., cell score=0) on postoperative day (POD) 8. The presence of anterior cells was assessed using a slit lamp binocular microscope up to 30 days post treatment. The percentage of patients with anterior chamber clearing at Day 8 was 20% in the placebo group, and 57%, and 60% in the 342 and 517 microgram treatment groups, respectively (Table 1). The percentage of subjects receiving rescue medication of ocular steroid or NSAID was significantly lower at Day 3, 8, 15 and 30 in the 342 and 517 microgram treatment groups compared to placebo (Table 2).

Table 1: Proportion of subjects with clearing of the anterior chamber cells by visit

Visits	Treatments			Difference and 97.5% CI	
	Placebo N=80	DEX342 N=158	DEX517 N=156	DEX342 vs Placebo	DEX517 vs Placebo
Day 1	7 (9%)	17 (11%)	24 (15%)	2% (-7%, 11%)	7% (-3%, 16%)
Day 3	13 (16%)	60 (38%)	44 (28%)	22% (9%, 34%)	12% (0%, 24%)
Day 8	16 (20%)	90 (57%)	94 (60%)	37% (24%, 50%)	40% (27%, 54%)
Day 15	21 (26%)	83 (52%)	91 (58%)	26% (12%, 40%)	32% (18%, 46%)
Day 30	28 (35%)	113 (72%)	103 (66%)	36% (22%, 51%)	31% (16%, 46%)

Subjects who received rescue medication were treated as failure.

Table 2: Proportion of subjects receiving rescue medications

Visits	Number (Percent) of Patients Receiving Rescue Medication, and 95% CI		
	Placebo N=80	DEX342 N=158	DEX517 N=156
Day 1	10 (13%); 6%, 22%	9 (6%); 3%, 10%	10 (6%); 3%, 12%
Day 3	30 (38%); 27%, 49%	9 (6%); 3%, 10%	16 (10%); 6%, 16%
Day 8	40 (50%); 39%, 61%	12 (8%); 4%, 13%	16 (10%); 6%, 16%
Day 15	43 (54%); 42%, 65%	22 (14%); 9%, 20%	26 (17%); 11%, 24%
Day 30	43 (54%); 42%, 65%	25 (16%); 10%, 22%	31 (20%); 14%, 27%

Subjects who received an ocular corticosteroid or NSAID in study eye.

CLINICAL STUDIES

Results presented here are from a randomized, phase 3 clinical trial comparing the efficacy of DEXYCU 342 mcg and 517 mcg to placebo (N=394).

The primary endpoint was anterior chamber (AC) cell clearing at Day 8.

Note: Only the 517 mcg dose is commercially available.

PROPORTION OF SUBJECTS WITH CLEARING OF AC CELLS BY VISIT (TABLE 1)

Results showed that DEXYCU demonstrated a higher rate of AC cell clearing than placebo starting on Day 3. AC cell clearing continued to increase over time.

- At Day 8 (primary endpoint), 60% of patients in the DEXYCU 517 mcg arm demonstrated AC cell clearing vs 20% in the placebo arm (97.5% confidence interval [CI]: 27%, 54%)

PROPORTION OF SUBJECTS RECEIVING RESCUE MEDICATIONS (TABLE 2)

The percentage of subjects receiving rescue medication of ocular steroid or NSAID was significantly lower at Day 3, 8, 15 and 30 in the 517 mcg treatment group compared to placebo.

16 HOW SUPPLIED/STORAGE AND HANDLING

Each kit of DEXYCU contains a single dose for a single patient. The 2-mL glass vial is filled with 0.5 mL of 9% dexamethasone intraocular suspension and has a blue cap (NDC # 71879-001-01).

Each kit also contains one sterile 18-gauge, 1.5-inch needle with a plastic cap attached, one sterile plastic 1-mL syringe for withdrawal of the vial contents, one sterile 25-gauge 8-mm cannula with a plastic cap attached for the intraocular administration, and one syringe assembly pouch containing a sterile ring and a sterile syringe guide used for measuring and injection of the 0.005 mL dose.

Store at 20°C to 25°C (68°F to 77°F).

Manufactured for: EyePoint Pharmaceuticals US, Inc. Watertown, MA 02472

HOW SUPPLIED/STORAGE AND HANDLING

Each DEXYCU kit contains a single dose for a single patient and the supplies needed to prepare and administer the dose.

Remember to store the kit at 20°C to 25°C (68°F to 77°F). Refrigeration is not necessary.



Please see full Prescribing Information in pocket.

DEXYCU and the EyePoint logo are trademarks of EyePoint Pharmaceuticals, Inc.



©2019 EyePoint Pharmaceuticals, Inc. All rights reserved.
480 Pleasant Street, Suite B300, Watertown, MA 02472


01/2019
US-DEX-1900004

Step 10.

Remove the syringe guide, leaving the syringe ring in place.

Caution to not move the plunger. The space between the syringe ring and the top of the plunger is the medication injection volume that will be applied to the patient's eye.


The syringe is now ready for injection.



Step 11.

In a single slow motion, inject 0.005 mL of the drug material behind the iris in the inferior portion of the posterior chamber. If the sphere of administered drug after intraocular injection appears to be larger than 2 mm in diameter, excess drug material may be removed by irrigation and aspiration in the sterile surgical setting.

PLEASE NOTE: Some drug material will remain in the syringe after the injection—this is necessary for accurate dosing. Discard unused portion remaining in the syringe after administration.



3 DOSAGE FORMS AND STRENGTHS

DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Increase in Intraocular Pressure

Prolonged use of corticosteroids including DEXYCU may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma.

5.2 Delayed Healing

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of corticosteroids.

5.3 Exacerbation of Infection

The use of DEXYCU, as with other ophthalmic corticosteroids, is not recommended in the presence of most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures.

Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection.

5.4 Cataract Progression

The use of corticosteroids in phakic individuals may promote the development of posterior subcapsular cataracts.

6 ADVERSE REACTIONS

The following adverse reactions are described elsewhere in the labeling:

- Increase in Intraocular Pressure [see *Warning and Precautions* (5.1)]
- Delayed Healing [see *Warnings and Precautions* (5.2)]
- Infection Exacerbation [see *Warnings and Precautions* (5.3)]
- Cataract Progression [see *Warnings and Precautions* (5.4)]

6.1 Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The following adverse events rates are derived from three clinical trials in which 339 patients received the 517 microgram dose of DEXYCU. The most commonly reported adverse reactions occurred in 5-15% of subjects and included increases in intraocular pressure, corneal edema and iritis. Other ocular adverse reactions occurring in 1-5% of subjects included, corneal endothelial cell loss, blepharitis, eye pain, cystoid macular edema, dry eye, ocular inflammation, posterior capsule opacification, blurred vision, reduced visual acuity, vitreous floaters, foreign body sensation, photophobia, and vitreous detachment.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no adequate and well-controlled studies of DEXYCU (dexamethasone intraocular suspension) 9% in pregnant women. Topical ocular administration of dexamethasone in mice and rabbits during the period of organogenesis produced cleft palate and embryofetal death in mice and malformations of abdominal wall/intestines and kidneys in rabbits at doses 7 and 5 times higher than the injected recommended human ophthalmic dose (RHOD) of DEXYCU (517 micrograms dexamethasone), respectively [see *Data*].

In the US general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

Topical ocular administration of 0.15% dexamethasone (0.75 mg/kg/day) on gestational days 10 to 13 produced embryofetal lethality and a high incidence of cleft palate in mice. A dose of 0.75 mg/kg/day in the mouse is approximately 7-times the injected RHOD of DEXYCU, on a mg/m² basis. In rabbits, topical ocular administration of 0.1% dexamethasone throughout organogenesis (0.20 mg/kg/day on gestational day 6, followed by 0.13 mg/kg/day on gestational days 7 – 18) produced intestinal anomalies, intestinal aplasia, gastroschisis and hypoplastic kidneys. A dose of 0.13 mg/kg/day in the rabbit is approximately 5-times the injected RHOD of DEXYCU, on a mg/m² basis. A no-observed-adverse-effect-level (NOAEL) was not identified in the mouse or rabbit studies.

8.2 Lactation

Risk Summary

Systemically administered corticosteroids are present in human milk and can suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. There is no information regarding the presence of injected DEXYCU in human milk, the effects on breastfed infants, or the effects on milk production to inform risk of DEXYCU to an infant during lactation. The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for DEXYCU and any potential adverse effects on the breastfed child from DEXYCU.

8.4 Pediatric Use

Safety and effectiveness of DEXYCU in pediatric patients have not been established.


8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between older and younger patients.

11 DESCRIPTION

DEXYCU (dexamethasone intraocular suspension) 9% is a corticosteroid, sterile, white to off-white opaque suspension for intraocular administration. Each vial of DEXYCU contains 0.5 mL of 9% w/w dexamethasone suspension equivalent to 51.7 mg of dexamethasone. The inactive ingredient is acetyl triethyl citrate. DEXYCU does not contain an antimicrobial preservative.

The chemical name of dexamethasone is pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)-. It has a molecular formula of C₂₂H₂₉FO₅ and a molecular weight of 392.46 grams per mole. Its structural formula is:



12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Dexamethasone is a corticosteroid. Corticosteroids have been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

12.3 Pharmacokinetics

Systemic exposure to dexamethasone was evaluated in a subgroup of patients enrolled in two studies (n=25 for the first study and n=13 for the second study). The patients received a single intraocular injection of DEXYCU containing 342 mcg or 517 mcg of dexamethasone at the end of cataract surgery and blood samples were collected prior to surgery and at several time points post-surgery between Day 1 and up to Day 30. In the first study, the dexamethasone plasma concentrations on post-surgery Day 1 ranged from 0.09 to 0.86 ng/mL and from 0.07 to 1.16 ng/mL following administration of DEXYCU 342 mcg and 517 mcg, respectively. In the second study, dexamethasone plasma concentrations on post-surgery Day 1 ranged from 0.349 to 2.79 ng/mL following administration of DEXYCU 517 mcg. In both the studies, dexamethasone plasma concentrations declined over time and very few patients had quantifiable dexamethasone plasma concentrations at the final time point of sampling (Day 15 or Day 30).

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Animal studies have not been conducted to determine whether DEXYCU has the potential for carcinogenesis or mutagenesis. Fertility studies have not been conducted in animals

14 CLINICAL STUDIES

Clinical efficacy was evaluated in a randomized, double-masked, placebo-controlled trial (NCT02006888) in which subjects received either DEXYCU or placebo (vehicle). A dose of 5 microliters of DEXYCU (equivalent to 517 micrograms of dexamethasone), a dose equivalent to 342 micrograms of dexamethasone or vehicle was administered by the physician at the end of the surgical procedure. The primary efficacy endpoint for the study was the proportion of patients with anterior chamber cell clearing (i.e., cell score=0) on postoperative day (POD) 8. The presence of anterior cells was assessed using a slit lamp binocular microscope up to 30 days post treatment. The percentage of patients with anterior chamber clearing at Day 8 was 20% in the placebo group, and 57%, and 60% in the 342 and 517 microgram treatment groups, respectively (Table 1). The percentage of subjects receiving rescue medication of ocular steroid or NSAID was significantly lower at Day 3, 8, 15 and 30 in the 342 and 517 microgram treatment groups compared to placebo (Table 2).

Table 1: Proportion of subjects with clearing of the anterior chamber cells by visit

Visits	Treatments			Difference and 97.5% CI	
	Placebo N=80	DEX342 N=158	DEX517 N=156	DEX342 vs Placebo	DEX517 vs Placebo
Day 1	7 (9%)	17 (11%)	24 (15%)	2% (-7%, 11%)	7% (-3%, 16%)
Day 3	13 (16%)	60 (38%)	44 (28%)	22% (9%, 34%)	12% (0%, 24%)
Day 8	16 (20%)	90 (57%)	94 (60%)	37% (24%, 50%)	40% (27%, 54%)
Day 15	21 (26%)	83 (52%)	91 (58%)	26% (12%, 40%)	32% (18%, 46%)
Day 30	28 (35%)	113 (72%)	103 (66%)	36% (22%, 51%)	31% (16%, 46%)

Subjects who received rescue medication were treated as failure.

Table 2: Proportion of subjects receiving rescue medications

Visits	Number (Percent) of Patients Receiving Rescue Medication, and 95% CI		
	Placebo N=80	DEX342 N=158	DEX517 N=156
Day 1	10 (13%); 6%, 22%	9 (6%); 3%, 10%	10 (6%); 3%, 12%
Day 3	30 (38%); 27%, 49%	9 (6%); 3%, 10%	16 (10%); 6%, 16%
Day 8	40 (50%); 39%, 61%	12 (8%); 4%, 13%	16 (10%); 6%, 16%
Day 15	43 (54%); 42%, 65%	22 (14%); 9%, 20%	26 (17%); 11%, 24%
Day 30	43 (54%); 42%, 65%	25 (16%); 10%, 22%	31 (20%); 14%, 27%

Subjects who received an ocular corticosteroid or NSAID in study eye.

16 HOW SUPPLIED/STORAGE AND HANDLING

Each kit of DEXYCU contains a single dose for a single patient. The 2-mL glass vial is filled with 0.5 mL of 9% dexamethasone intraocular suspension and has a blue cap (NDC # 71879-001-01).

Each kit also contains one sterile 18-gauge, 1.5-inch needle with a plastic cap attached, one sterile plastic 1-mL syringe for withdrawal of the vial contents, one sterile 25-gauge 8-mm cannula with a plastic cap attached for the intraocular administration, and one syringe assembly pouch containing a sterile ring and a sterile syringe guide used for measuring and injection of the 0.005 mL dose.

Store at 20°C to 25°C (68°F to 77°F).

Manufactured for: EyePoint Pharmaceuticals US, Inc. Watertown, MA 02472